Replimune Announces Type A Meeting Scheduled with FDA
1. Replimune's FDA meeting scheduled to discuss RP1's complete response letter. 2. Company emphasizes urgent need for RP1 in advanced melanoma treatment. 3. Accelerated approval is crucial for continuing RP1 program. 4. RP1 is Replimune’s lead candidate for treating advanced melanoma.